Actively Recruiting
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
Led by Nanfang Hospital, Southern Medical University · Updated on 2024-03-12
300
Participants Needed
5
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Head and neck squamous cell carcinoma (SCC) is the sixth most common cancer worldwide, with more than 700,000 new cases and more than 350,000 deaths each year. At present, radiotherapy is an important measure to control the recurrence of head and neck tumors, but almost all patients with head and neck squamous cell carcinoma will have acute inflammatory reactions such as radiotherapy-induced oral mucositis (RIOM) after radiotherapy, which seriously affects the quality of life and radiotherapy efficacy of patients. Serum amyloid A1 (SAA1) is an acute phase protein associated with inflammation. Our previous basic research found that serum SAA1 expression levels can be used as biomarkers to assess the dose received by the receptor in the early stages of radiation damage. At the same time, we confirmed that the serum level of SAA1 in patients with nasopharyngeal carcinoma increased after radiotherapy. Therefore, we intend to conduct a prospective, multicenter, observational study to further explore the predictive power of plasma SAA1 levels for radiotherapy-induced oral mucositis, with a view to early screening and prevention of RIOM patients.
CONDITIONS
Official Title
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 18 years of age
- Voluntarily sign informed consent
- Pathological diagnosis of nasopharyngeal carcinoma or head and neck tumor
- Need to be treated with radiotherapy
- ECOG performance status score of 0 or 1
You will not qualify if you...
- Contraindications to radiotherapy
- Presence of other tumors
- Serious coexisting medical conditions like unstable heart disease, chronic hepatitis, kidney disease, uncontrolled diabetes, or mental illness
- Investigator decision deeming participant unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Nanfang hospital, Southern medical university
Guangzhou, Guangdong, China, 510515
Actively Recruiting
2
Fujian Provinical Hospital
Fuzhou, China
Not Yet Recruiting
3
Huizhou Central People's Hospital
Huizhou, China
Not Yet Recruiting
4
Jieyang People's Hospital
Jieyang, China
Not Yet Recruiting
5
Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou
Meizhou, China
Not Yet Recruiting
Research Team
J
Jian Guan, Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here